Invention Grant
- Patent Title: 3,3-difluoropiperidine carbamate heterocyclic compounds as NR2B NMDA receptor antagonists
-
Application No.: US15578460Application Date: 2016-05-31
-
Publication No.: US10584127B2Publication Date: 2020-03-10
- Inventor: Gideon Shapiro
- Applicant: Rugen Holdings (Cayman) Limited
- Applicant Address: BM Grand Cayman
- Assignee: Rugen Holdings (Cayman) Limited
- Current Assignee: Rugen Holdings (Cayman) Limited
- Current Assignee Address: BM Grand Cayman
- Agency: Choate, Hall & Stewart LLP
- Agent Brenda H. Jarrell; Kristen C. Buteau
- International Application: PCT/US2016/035098 WO 20160531
- International Announcement: WO2016/196513 WO 20161208
- Main IPC: A61K31/4545
- IPC: A61K31/4545 ; C07D487/04 ; C07D401/12 ; A61P25/28 ; A61P25/24 ; A61P25/08 ; A61P25/16 ; A61P25/06
Abstract:
Disclosed are chemical entities of Formula (I), wherein R1 and Z are defined herein, as NR2B subtype selective receptor antagonists. Also disclosed are pharmaceutical compositions comprising a chemical entity of Formula (I), and methods of treating various diseases and disorders associated with NR2B antagonism, e.g., diseases and disorders of the CNS, such as depression, by administering a chemical entity of Formula (I).
Public/Granted literature
- US20180170935A1 3,3-DIFLUOROPIPERIDINE CARBAMATE HETEROCYCLIC COMPOUNDS AS NR2B NMDA RECEPTOR ANTAGONISTS Public/Granted day:2018-06-21
Information query
IPC分类:
